Announcements

  • FDA fast-tracks Finch’s microbiome capsule for C. difficile

    7 years ago
    Microbiome company Finch Therapeutics Group announced that the FDA has issued Fast Track designation to CP101, its oral microbiome capsule in development for recurrent Clostridium difficile infection.